相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current directions in tau research: Highlights from Tau 2020
Claire Sexton et al.
ALZHEIMERS & DEMENTIA (2022)
Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington's disease
Isaline Mees et al.
HUMAN MOLECULAR GENETICS (2022)
Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington's Disease Mice Prior to Onset of Symptoms
Isaline Mees et al.
MOLECULAR NEUROBIOLOGY (2022)
Passive immunization against phosphorylated tau improves features of Huntington's disease pathology
Melanie Alpaugh et al.
MOLECULAR THERAPY (2022)
Huntington's Disease Clinical Trials Corner: April 2022
Carlos Estevez-Fraga et al.
JOURNAL OF HUNTINGTONS DISEASE (2022)
Gene targeting techniques for Huntington's disease
Eric Fields et al.
AGEING RESEARCH REVIEWS (2021)
Inhibition of GSK-3 ameliorates the pathogenesis of Huntington?s disease
Ido Rippin et al.
NEUROBIOLOGY OF DISEASE (2021)
Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease
Marta Fernandez-Nogales et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2020)
Targeting Tau to Treat Clinical Features of Huntington's Disease
Maria Masnata et al.
FRONTIERS IN NEUROLOGY (2020)
Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease
Judith Schilling et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Contrasting characteristic behaviours among common laboratory mouse strains
Razia Sultana et al.
ROYAL SOCIETY OPEN SCIENCE (2019)
A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington's disease patients
Peng Liu et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Tau pathology in cognitively normal older adults
Jacob Ziontz et al.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)
Tau-targeting therapies for Alzheimer disease
Erin E. Congdon et al.
NATURE REVIEWS NEUROLOGY (2018)
Co-occurrence of mixed proteinopathies in late-stage Huntington's disease
Isabelle St-Amour et al.
ACTA NEUROPATHOLOGICA (2018)
PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
Ivan Koychev et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Tau Protein in Oral Mucosa and cognitive state: a cross-sectional study
Luis Fernando Arredondo et al.
FRONTIERS IN NEUROLOGY (2017)
EuroTau: towing scientists to tau without tautology
Amrit Mudher et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease
Alexandre Bejanin et al.
BRAIN (2017)
Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease
Giulia Cisbani et al.
BRAIN (2017)
Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease
Shieh-Yueh Yang et al.
NEUROLOGY AND THERAPY (2017)
Roles of tau protein in health and disease
Tong Guo et al.
ACTA NEUROPATHOLOGICA (2017)
Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
Filipe Brogueira Rodrigues et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Caspase-2 cleavage of tau reversibly impairs memory
Xiaohui Zhao et al.
NATURE MEDICINE (2016)
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
Matthew R. Brier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions
F. L'Episcopo et al.
CELL DEATH & DISEASE (2016)
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases
Stephen N. Gomperts et al.
JAMA NEUROLOGY (2016)
Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease
Tua Vinther-Jensen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
The role of tau in the pathological process and clinical expression of Huntington's disease
Romina Vuono et al.
BRAIN (2015)
Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease
Marta Fernandez-Nogales et al.
HUMAN MOLECULAR GENETICS (2015)
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients
Edward J. Wild et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Mutant huntingtin alters Tau phosphorylation and subcellular distribution
David Blum et al.
HUMAN MOLECULAR GENETICS (2015)
Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease
Maud Gratuze et al.
HUMAN MOLECULAR GENETICS (2015)
Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis
Shinji Matsunaga et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain
Nastasia K. H. Lim et al.
HUMAN MOLECULAR GENETICS (2014)
Huntington's disease is a four-repeat tauopathy with tau nuclear rods
Marta Fernandez-Nogales et al.
NATURE MEDICINE (2014)
The Co-Occurrence of Alzheimer's Disease and Huntington's Disease: A Neuropathological Study of 15 Elderly Huntington's Disease Subjects
Marie Y. Davis et al.
JOURNAL OF HUNTINGTONS DISEASE (2014)
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Kirupa Sathasivam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Off label use of lithium in the treatment of Huntington's disease: A case series
Vijay Danivas et al.
INDIAN JOURNAL OF PSYCHIATRY (2013)
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion
Xiaomin Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
Peter T. Nelson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease
Karen Neumann et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
Salivary Tau Species are Potential Biomarkers of Alzheimer's Disease
Min Shi et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
Nuclear Tau, a Key Player in Neuronal DNA Protection
Audrey Sultan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
Jeffrey B. Carroll et al.
MOLECULAR NEURODEGENERATION (2011)
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
Cristian A. Lasagna-Reeves et al.
MOLECULAR NEURODEGENERATION (2011)
Combined Treatment with the Mood Stabilizers Lithium and Valproate Produces Multiple Beneficial Effects in Transgenic Mouse Models of Huntington's Disease
Chi-Tso Chiu et al.
NEUROPSYCHOPHARMACOLOGY (2011)
PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum
A. Saavedra et al.
CELL DEATH AND DIFFERENTIATION (2010)
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease
Amber L. Southwell et al.
JOURNAL OF NEUROSCIENCE (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Association of Corticobasal Degeneration and Huntington's Disease: Can Tau Aggregates Protect Huntingtin Toxicity?
Dominique Caparros-Lefebvre et al.
MOVEMENT DISORDERS (2009)
Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity
Xavier Xifro et al.
NEUROBIOLOGY OF DISEASE (2009)
A novel GSK-3 beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
L. Sereno et al.
NEUROBIOLOGY OF DISEASE (2009)
Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
Jose R. Pineda et al.
MOLECULAR BRAIN (2009)
Regional and cellular gene expression changes in human Huntington's disease brain
A Hodges et al.
HUMAN MOLECULAR GENETICS (2006)
Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421
R Pardo et al.
JOURNAL OF NEUROSCIENCE (2006)
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo
W Noble et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c•SRp55 complex that either recruits or antagonizes htra2β1
YZ Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease
E Trushina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport
G Szebenyi et al.
NEURON (2003)
Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation
NI Wood et al.
BRAIN RESEARCH BULLETIN (2003)
The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt
S Humbert et al.
DEVELOPMENTAL CELL (2002)
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
N Andreasen et al.
ARCHIVES OF NEUROLOGY (2001)
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
R Luthi-Carter et al.
HUMAN MOLECULAR GENETICS (2000)
分享论文
